mabthera-ra.com — Roche announces that MabThera (rituximab) has been approved by the European Commission for the treatment of rheumatoid arthritis. MabThera in combination with methotrexate is indicated for adult rheumatoid arthritis patients who have had an inadequate response or are intolerant to current treatment options including one or more TNF inhibitors.